guidance.fyi
Company, ticker, metric, guidance, or anything said
VerifiedNumbers checked and claims independently audited

Q1 FY27 concall · earnings callMedi Assist Healthcare Services Limited

Medi Assist delivered strong overall revenue growth, advanced its three strategic growth engines—India TPA, technology platform, and international expansion—and is progressing on margin recovery post-acquisition integration.

Positive tone5-minute briefPublished 8 days after the call

Numbers
MetricThis quarterChangeFive-quarter trend
Total Income₹247 Cr24.9% YoY
Operating Revenue₹236.5 Cr24.1% YoY
Operating EBITDA Margin20.3%—
Reported PAT₹27.6 Cr—
Adjusted PAT₹24.5 Cr—
Group Segment Revenue Growth25.5% year-on-year—
Retail Segment Revenue Growth13.1% year-on-year—
Government Segment Revenue Growth35.3% year-on-year—
Financials

From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.

QuarterRevenueNet profit (PAT)Basic EPS
Q3 FY25₹185.97 Cr+12% YoY+2.9% QoQ₹29.97 Cr+41.5% YoY+42.6% QoQ₹4.19+39.7% YoY+40.6% QoQ
Q2 FY25₹180.77 Cr— YoY+7.8% QoQ₹21.01 Cr— YoY+10.9% QoQ₹2.98— YoY+10.4% QoQ
Q1 FY25₹167.71 Cr— YoY+0.6% QoQ₹18.95 Cr— YoY-25.7% QoQ₹2.70— YoY-26.4% QoQ
Q4 FY24₹166.79 Cr— YoY+0.5% QoQ₹25.51 Cr— YoY+20.4% QoQ₹3.67— YoY+22.3% QoQ
Q3 FY24₹165.98 Cr— YoY— QoQ₹21.18 Cr— YoY— QoQ₹3.00— YoY— QoQ
TL;DR
  • Total income grew 24.9% YoY to INR247 crores.
  • EBITDA margin improved sequentially for the fourth straight quarter to 20.3% on operating revenue.
  • Technology SaaS business revenue grew 55.5% YoY and now represents 3.3% of consolidated revenues.
  • Group TPA retention was 90.2%, impacted by post-acquisition transition and portfolio rationalization.
  • The company completed over 90% ownership in its international subsidiary Mayfair and launched its first tech contract in Thailand.
  • Management expects to complete the remaining Paramount TPA integration in Q2 FY27 and normalize margins through FY27.
Said on the call

“It is important that I stress that nothing about who runs Medi Assist changes on the 8th of September.”

Vikram Chhatwal
From the Q&A
TopicWhat management said
Execution Priorities and RisksManagement outlined three priorities: transforming the India TPA business to be leaner and more digital, converting the technology business pipeline, and building long-term moats in the international business. They view their unique position at the intersection of stakeholders and AI-led technology as a key mitigant to risks.
Financial Risk ManagementThe key focus is completing the Paramount integration to improve margins and reducing receivables by improving collections, with DSOs already showing a 4.5 percentage improvement year-on-year.
Government Business Working CapitalManagement stated the government business is margin accretive, collections are safe from state/central governments, and it does not lead to an elongated working capital cycle or cash flow strain, with consolidated DSOs improving.
EBITDA Margin RecoveryThe immediate goal is to finish Paramount integrations and get back to the pre-integration margin level of 22-23% by the end of FY27.
Retail Business TrajectoryManagement clarified that the reported retail TPA revenue does not capture all platform-administered work; investors should look at total retail market access (TPA + platform) plus technology revenues to gauge market share improvement.
Overall Business Growth OutlookCore group and retail segments are expected to grow at par or faster than the market, technology business is growing fast from a small base (3.3% of revenue), and the international business has potential for higher yields despite a soft Q1.
Group TPA Organic GrowthRetention is at 90% due to portfolio rationalization and onboarding challenges post-acquisition. Same-store growth is holding around 8%, similar to last year, with IT companies slower but others faster.
Outcome-Based ContractsThe company has signed its first outcomes-based contract tied to fraud, waste, and abuse savings, but no specifics were shared.
Guidance
  • Target full migration of remaining Paramount claims and operations to Medi Assist stack within Q2 FY27.
  • Expect the near-term PHS retention drag to get fully normalized through FY27.
  • Aim to get EBITDA margins back to pre-Paramount integration levels (22-23%) towards the end of FY27.
  • Expect technology and international businesses to become meaningful contributors to growth and EBITDA margins over time.
Source
Same sector

Others in Pharmaceuticals & Healthcare

All Pharmaceuticals & Healthcare →
  • Symbiotec Pharmalab LimitedQ1 FY27Positive tone

    Q1 FY27 was driven by the established steroid API business while consolidated profit was reduced by operating costs and depreciation from the new biotech CDMO and complex injectables facilities awaiting first revenues in the next 6 to 12 months.

    Consolidated revenue Q1 FY27
    ₹218 Crgrowth of 7% YoY
    API revenue Q1 FY27
    ₹215 Crgrowth of 6% YoY
    SYMBIOTECPharmaceuticals & HealthcareVerified brief6 guidance items
  • Molbio Diagnostics LimitedQ1 FY27Positive tone

    Q1 FY27 was led by the Truenat point-of-care molecular platform with recurring kit sales driving revenue, while management pointed to TB scale-up, HPV rollout, and U.S. and Europe expansion as next growth drivers.

    Revenue from operations (Q1 FY27)
    ₹408 Cr
    EBITDA (Q1 FY27)
    ₹104 Cr
    MOLBIOPharmaceuticals & HealthcareVerified brief3 guidance items
  • Fischer Medical Ventures LtdQ1 FY27Neutral tone

    Fischer Medical Ventures used its September 7, 2026 investor call to present its AI-enabled imaging platform, proprietary technology stack and leadership team, without disclosing quarterly financial results.

    FISCHERPharmaceuticals & HealthcareVerified brief
  • Fortis Healthcare LimitedQ1 FY27Positive tone

    Delhi High Court ordered a court-supervised forensic audit into erstwhile promoter share dissipation, IHH's acquisition of control and use of funds for RHT assets, which Fortis and IHH say leaves operations, capex, bed expansion and M&A unrestricted and is expected to have no material adverse outcome.

    FORTISPharmaceuticals & HealthcareVerified brief4 guidance items
  • Orchid Pharma LimitedQ1 FY27Cautious tone

    Quarterly revenue improved 15% year-over-year and EBITDA grew on better gross margins, but the core cephalosporin business continues to face intense industry pricing pressure.

    Revenue from Operations
    ₹304 Crapprox. 15%
    Combined Gross Margin
    33%approx. 3% points
    ORCHPHARMAPharmaceuticals & HealthcareVerified brief6 guidance items